Systemic Therapy for Melanoma

Publication Date: August 14, 2023

Key Points

Key Points

  • The clinical burden associated with the treatment of melanoma has been increasing due to rising incidence globally.
  • Since 2011, 12 new drugs have been approved for unresectable melanoma and 4 additional drugs have been approved in the adjuvant setting.
  • Overall survival for melanoma is improving rapidly, with dramatic increases in long-term survival observed from administration of these new therapies.
  • This guideline includes recommendations on uveal melanoma based on new clinical trial data.

Treatment

...eatment

...vant Systemic Therapy...

...neous Melanoma Eligible for Re...

...ion 1.1.Neoadjuvant pembrolizumab (maximum of...

...on 1.2.Patients with clinical and res...


...nt Systemic Thera...

...Stage II, III, IV) Cutaneous Melanoma...

...ecommendation 2.1.1.Adjuvant pembrolizuma...

...on 2.1.2.Adjuvant therapy should not be...

Recommendation 2.2.For patients with resected stag...

...dation 2.3.For patients with resected stage IIIAâ...

...ndation 2.4.No recommendation can be made for o...

...ecommendation 2.5.1.Patients with r...

...ndation 2.5.2....

...alone (Evidence Quality - Medium) (...

...ipilimumab followed by nivolumab ( IC , L ,...

...umab alone ( IC , L , , W )333...

...b plus trametinib (in patients with BRAF V600E/K...


...ystemic Therapy Opt...

...sectable/Metastatic Cutaneous Me...

...on 3.1.For patients with BRAF wild-ty...

...tion 3.2.1.For patients with BRAF mutant (V600)...

...ommendation 3.2.2....

...erapy with nivolumab plus ipilimumab is preferred...

...ation therapy with nivolumab plus ipilimumab is pr...

...endation 3.3.After progression on anti-PD-1-based...

...commendation 3.4.After progression on 1st...

...ommendation 3.5.For patients with injectab...

...taneous Melanoma (Stage II or Greater)...

...tion 4.1.1.HLA-A*02:01-positive patient...

...ecommendation 4.1.2.For all patients with u...

...ommendation 4.2.In the absence of further dat...

...ion 4.3.No recommendation for or a...


...1. Reasonable Dose and Schedule Details f...


...able 2. Reasonable Dose and Schedule Detail...


...temic Therapy for Melanoma...


...temic Therapy for Melanoma (cont'd...